SCHEMBL10115657

SCHEMBL10115657

CC(C)(C)S(=O)(=O)NC1CCN(C(=O)Nc2ccc(-c3ccccc3)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CCR8 P51685 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TRPV1 Q8NER1 1/20 0.47
KDM4E B2RXH2 2/20 0.47
NPY5R Q15761 1/20 0.47
POLB P06746 2/20 0.47
ALOX15 P16050 1/20 0.47
FAAH O00519 3/20 0.46
EPHX2 P34913 1/20 0.46
RBP4 P02753 1/20 0.46
KMT2A Q03164 1/20 0.45
MCHR1 Q99705 1/20 0.45
GAA P10253 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115579 0.93 ALDH1A1 (0.55) LMNANPSR1CCR8ALDH1A1KDM4E
SCHEMBL10115613 0.89 NPY5R (0.48) LMNANPSR1CCR8ALDH1A1KDM4E
SCHEMBL10115619 0.88 LMNA (0.47) LMNANPSR1CCR8ALDH1A1TRPV1
SCHEMBL12882928 0.88 EPHX2 (0.53) LMNANPSR1CCR8ALDH1A1NPY5R
SCHEMBL10115527 0.87 LMNA (0.66) LMNANPSR1KDM4EPOLBALOX15
SCHEMBL12882021 0.87 LMNA (0.53) LMNANPSR1CCR8ALDH1A1KDM4E
SCHEMBL10115617 0.87 LMNA (0.53) LMNANPSR1CCR8ALDH1A1POLB
SCHEMBL10115738 0.87 LMNA (0.49) LMNANPSR1CCR8TRPV1POLB
SCHEMBL10115628 0.87 KMT2A (0.52) LMNANPSR1CCR8ALDH1A1KMT2A
SCHEMBL10115664 0.86 LMNA (0.50) LMNANPSR1CCR8POLBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R LMNA 1925/4885NPSR1 7/4885CCR8 429/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885NPSR1 8/4885CCR8 394/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 1857/4885NPSR1 7/4885CCR8 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.